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Abstract
Allantoin is the end product of purine catabolism in all mammals except humans, great apes, and one breed of dog, the
Dalmatian. Humans and Dalmatian dogs produce uric acid during purine degradation, which leads to elevated levels of uric
acid in blood and urine and can result in significant diseases in both species. The defect in Dalmatians results from
inefficient transport of uric acid in both the liver and renal proximal tubules. Hyperuricosuria and hyperuricemia (huu) is a
simple autosomal recessive trait for which all Dalmatian dogs are homozygous. Therefore, in order to map the locus, an
interbreed backcross was used. Linkage mapping localized the huu trait to CFA03, which excluded the obvious urate
transporter 1 gene, SLC22A12. Positional cloning placed the locus in a minimal interval of 2.5 Mb with a LOD score of 17.45.
A critical interval of 333 kb containing only four genes was homozygous in all Dalmatians. Sequence and expression
analyses of the SLC2A9 gene indicated three possible mutations, a missense mutation (G616T;C188F) and two promoter
mutations that together appear to reduce the expression levels of one of the isoforms. The missense mutation is associated
with hyperuricosuria in the Dalmatian, while the promoter SNPs occur in other unaffected breeds of dog. Verification of the
causative nature of these changes was obtained when hyperuricosuric dogs from several other breeds were found to
possess the same combination of mutations as found in the Dalmatian. The Dalmatian dog model of hyperuricosuria and
hyperuricemia underscores the importance of SLC2A9 for uric acid transport in mammals.
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Introduction
Uric acid is the predominant product of purine metabolism in
humans, great apes and one breed of dog, the Dalmatian; all other
mammals excrete allantoin. During primate evolution, urate
oxidase (UOX), which catalyzes the oxidation of uric acid into
allantoin, accumulated several independent nonsense mutations
that led to its silencing and resulted in high serum and urine uric
acid levels in humans and great apes [1,2]. Huu in the Dalmatian
results from a different cause [3,4]. Uric acid freely circulates in
the form of urate, the salt of uric acid, in the plasma where it serves
as a free-radical scavenger. Although uric acid has evolved in
humans to be the main product of purine metabolism, this change
has had some negative effects. High levels of urate predispose
humans to gout [5,6]. In addition, uric acid levels have been
correlated with hypertension, vascular disease and metabolic
syndrome although it is unclear whether hyperuricemia is primary
or secondary in these cases [7–10].
As in humans, all Dalmatian dogs have a defect in urinary
metabolism that leads to excretion of uric acid rather than allantoin
[11]. As a result, Dalmatians are predisposed to form urinary calculi
composed of urate (Figure 1B). Hyperuricosuria in the Dalmatian is
relatively easy to identify since Dalmatian urine forms a crystallized
precipitate when cooled (Figure 1C). This trait was probably fixed in
the breed through selection for a more distinctive spotting pattern
[12,13]. Dalmatian coat pattern involves mutations in at least three
different spotting genes (Figure 1A). Dalmatians have a mutation for
extreme white in the MITF gene [14] that leads to an all white coat.
A dominant mutation, called T for ticking [15], is responsible for
adding the pigmented spots to the white coat. Based on segregation
analysis, the huu locus appears to be closely linked to a modifier of
spot size [16].
In mammals that produce uric acid rather than allantoin, the
level of uric acid in the blood is controlled by differences in
production as well as differences in the amount that is excreted in
the urine. In the kidney, uric acid is filtered by the glomerulus and
then a portion is reabsorbed in the proximal tubules where it re-
enters circulation. There are species-specific differences in the
production of uric acid versus allantoin and the relative amounts
of reabsorption and secretion in the proximal tubules, making the
use of animal models in this area of research challenging [17].
Dogs and humans, unlike many other mammals, undergo
bidirectional transport of urate along the nephron, which results in
net reabsorption of urate from the glomerular filtrate. In
Dalmatians, reabsorption is lost entirely and urate excretion
equals or exceeds the glomerular filtration rate [18]. This change
in uric acid excretion by the Dalmatian kidney is not secondary to
hyperuricemia since non-Dalmatian dogs with artificially raised
serum uric acid levels can only clear uric acid at ,1/3 the rate of
the Dalmatian [18]. Free-flow micropuncture experiments were
used to demonstrate that in Dalmatian kidneys there is a
deficiency of proximal tubular reabsorption of urate [19].
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Dalmatian huu, reciprocal liver and kidney transplant experiments
between Dalmatian and non-Dalmatian dogs demonstrate that the
liver is also important for the phenotype. Kidney transplants
between normal dogs and Dalmatians only partially ameliorated
the hyperuricosuria phenotype [20,21]. However, Dalmatian
hepatocyte transplants can correct the phenotype [20]. Therefore,
a logical cause for the Dalmatian phenotype is a mutation in urate
oxidase, similar to humans. However, Dalmatian liver homoge-
nates are capable of oxidizing uric acid to allantoin and the urate
oxidase gene was excluded genetically [3]. The Dalmatian
phenotype could also be explained by a generalized defect of
urate transport since liver slices were not capable of converting
uric acid to allantoin [4]. Dalmatian dog erythrocytes have been
shown to transport urate normally, demonstrating that Dalmatians
do not have a generalized defect in urate transport [22]. Although
Dalmatians have functional urate oxidase activity in their livers,
they effectively have a similar phenotype to humans and great apes
since they cannot transport urate into the liver for degradation.
The Dalmatian phenotype can be summarized as a hepatic and
renal urate transport defect which leads to hyperuricosuria and
relative (compared to other dogs) hyperuricemia.
The discovery of various proteins that transport urate has shed
some light on the control of serum and urine uric acid levels [23].
In the kidney, urate is transported across the apical membrane of
the proximal tubules and then across the basolateral membrane
before re-entering circulation. In humans, the transporter that
reabsorbs urate across the apical membrane in the proximal tubule
is Urat1, or SLC22A12 [24], which is expressed exclusively in the
kidney. Mutations in SLC22A12 are thought to be the major cause
of idiopathic renal hypouricemia in humans [24,25], which is also
called ‘‘Dalmatian hypouricemia’’ since people with this disorder
spill uric acid into their urine resulting in a phenotype similar to
the Dalmatian dogs [26]. In addition, recent work has shown an
association of SLC2A9 with serum uric acid levels in several
different populations [27,28]. Variants in the non-coding region of
SLC2A9 are associated with gout and uric acid levels in several
human populations [29–31]. SLC2A9 has been shown by Xenopus
oocyte experiments to transport uric acid [30]. In humans and
mice it is expressed in liver and kidney [32,33]. In particular, in
humans SLC2A9 isoforms have been localized to both the apical
and basolateral membrane of the proximal tubules, allowing the
possibility that SLC2A9 influences serum uric acid levels by
transport in the kidney [34].
All Dalmatians are homozygous for huu, which is inherited as a
simple autosomal recessive trait as demonstrated by crosses
performed between Dalmatians and other breeds of dogs
[12,13]. In order to identify the causative gene, an interbreed
backcross (Dalmatian6Pointer) was developed which introduced
the wildtype version of the huu gene into the Dalmatian breed
while maintaining the breed characteristics of the Dalmatian.
Based on linkage analysis using this cross (LOD 6.55), huu
localizes to CFA03, excluding SLC22A12 as a candidate [35].
Using recombination breakpoints in the interbreed backcross and
taking advantage of the homozygosity within the Dalmatian breed
for huu, a critical interval containing four candidate genes was
defined. Microsatellite markers within this interval gave LOD
scores over 17 for linkage to huu. A candidate causal missense
mutation (C188F) was identified within a highly conserved
transmembrane (TM5) of the 12 transmembrane transporter
Figure 1. The Dalmatian phenotype. (A) The characteristic spotting pattern exhibited by the breed. (B) Urinary urate calculi removed from a
Dalmatian. (C) Dalmatian urine crystallization: Dalmatian urine sample (left), urine from a heterozygous backcross dog (middle), and urine from a dog
from an unaffected breed (right).
doi:10.1371/journal.pgen.1000246.g001
Author Summary
Animals excrete waste products in their urine. When most
mammals metabolize compounds, called purines, they
produce allantoin as one waste product in their urine.
Humans, great apes, and Dalmatian dogs produce a
different breakdown product, uric acid. This leads to high
levels of uric acid in the urine and blood. In humans, this
can result in diseases such as kidney stones and gout and
may cause hypertension. In Dalmatians, high uric acid
levels result in bladder stones that often have to be
removed surgically. The cause of high uric acid levels in
humans and great apes is not the same as in the Dalmatian
dog. Here we report the genetic cause of the Dalmatian
condition. This change is shared by dogs from unrelated
breeds, indicating that it predates the separation of dog
breeds. The gene that causes excretion of uric acid in
Dalmatians is important for controlling the amount of uric
acid in human blood and is therefore important for human
diseases. It is not clear why humans and great apes have
evolved to excrete uric acid, but it appears that some dogs
have developed a different mechanism that leads to the
same result: elevations in urine and blood uric acid levels.
SLC2A9 and Hyperuricosuria
PLoS Genetics | www.plosgenetics.org 2 November 2008 | Volume 4 | Issue 11 | e1000246protein, SLC2A9. The missense mutation is homozygous in all
Dalmatians tested (247) as well as in hyperuricosuric dogs of other
breeds.
Results
Linkage analysis using a Dalmatian6Pointer backcross family
localized Dalmatian huu to CFA03. Haplotype analysis defined a
3.3 Mb critical interval (CFA03 72,063,073–75,355,028 Mb),
estimated to contain 24 candidate genes [35]. Additional backcross
dogs were genotyped with the microsatellites used for haplotype
analysis and with new microsatellites mined from the critical
region on CFA03. The full pedigree of all the dogs used for this
analysis is shown in Figure S1. Urine uric acid/creatinine ratios
were used to categorize the dogs’ genotypes at huu. LOD scores
were determined for a subset of these markers. Two markers
within the critical interval defined by recombination breakpoints
gave LOD scores over 17, further confirming the linkage to this
region. Recombination events in two dogs narrowed the critical
interval to a 2.5 Mb region containing 19 candidate genes
(CFA03; 71,796,048–74,348,350 Mb) (Figure 2).
Since Dalmatians are fixed for huu, it was expected that an area
of homozygosity around the huu locus would be identified. Blocks
of linkage disequilibrium (LD) in purebred dogs extend between
several megabases in rare breeds with small population sizes to
several kilobases in popular breeds with larger population sizes
[14,36]. Dalmatians have a moderate population size, so the
homozygous region surrounding huu should be smaller than
2.5 Mb. Microsatellites mined from the canine genome and
located ,100 Kb apart were genotyped in the backcross dogs.
Markers that were homozygous in huu/huu individuals and
heterozygous in huu/+ individuals were typed in 24 unrelated
Dalmatians to verify that the region of homozygosity is not the
result of familial linkage disequilibrium. Haplotypes were con-
structed to rule out the possibility of more than a single ancestral
mutation. Regions of homozygosity were found between ms173
and ms9 (CFA03; 71,796,048–72,363,187) and ms187 and ms128
(CFA03; 74,183,928–74,245,743). Eighteen SNPs, extending
across 2.5 Mb, were genotyped in 24 Dalmatians, a wild-type
Labrador Retriever and a huu/+ backcross dog. The results
excluded the area between ms187 and ms128 and a total of 13
SNPs spanning ,333 Kb confirmed the homozygous region
between ms173 and ms9 in the 24 Dalmatians (Figure 3). These
SNPs are also heterozygous in the huu/+ backcross dog,
polymorphic in two unaffected dogs (ND1 and ND2) and the
Boxer genome assembly sequence.
Four candidate genes were identified in the region of homozy-
gosity, LOC488823 (similar to mast cell immunoreceptor signal
transducer – MIST), LOC479092 (zinc finger protein 518B,
KIAA1729), LOC611070 (similar to WD-repeat protein 1 –
WDR1) and LOC479093 (similar to solute carrier family 2, member
9 protein, isoform 1 – SLC2A9) (Figure 3). RT-PCR established that
all four genes were expressed incanine liver and kidney. Since all the
candidates were expressed in the appropriate organs, all four genes
were sequenced from Dalmatian and non-Dalmatian liver cDNA
samples and the untranslated regions (UTRs) were determined by 59
and 39 RACE (Genbank EU371511–EU371515).
The 59UTR and exons 1–7 of MIST were outside of the LD
region and were not pursued. A single silent mutation was
identified in exon 16 of the MIST gene (T951C). Three silent
mutations were found in the single exon of the canine KIAA1729
gene (T932C, C2480T, G3092A) and a 33 bp insertion/deletion
was discovered in the 39UTR. Both alleles of these three SNPs and
the insertion/deletion were seen in unaffected non-Dalmatian
Figure 2. Fine structure mapping of the huu locus. (A) Physical map showing the location of the microsatellite markers used to map huu on
CFA03. Microsatellite markers are listed below the line, and distances in Mb are shown above the line. (B) The haplotypes of recombinant (Rec) and
non recombinant (Non Rec) backcross dogs are depicted with Dalmatian haplotypes in white and the Pointer haplotype in grey. A ‘‘V’’ indicates that
the alleles were variable in Dalmatians. The first recombinant was not informative for MS173. The recombinants localized huu between MS8 and
MS153. The maximum LOD score calculated for each microsatellite for all members of the family is shown at the bottom of the figure. The uric acid to
creatinine ratio (UA/Cr), with the standard deviation in parenthesis, the number of dogs in each class (#), and the inferred huu genotype (G) are
shown for dogs born since 2006 (28). The range of Uric acid/creatinine ratios for the low uric acid dogs is 0.23 to 0.47, and the range for high uric acid
dogs is 1.2 to 4.0.
doi:10.1371/journal.pgen.1000246.g002
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from a Dalmatian and a non-Dalmatian. A single SNP was found
in intron 9 that does not affect a splice site. Although SLC2A9 did
not have an assigned function related to uric acid metabolism at
the time this work was performed, it was considered to be the most
promising candidate since it is a transporter protein.
A discrepancy in SLC2A9 exon annotation between NCBI and
the UC Santa Cruz genome browser was addressed by 59 RACE.
Two SLC2A9 exon 1 variants were found in a Dalmatian and a
wild-type Golden Retriever, variant O (CFA03:72,222,637–
72,416,753) and variant N (CFA03: 72,227,605–72,416,753).
The difference between the two variants lies in the first 28 amino
acids of the N terminus, similar to known mouse and human
variants. Both transcripts were shown to be expressed in canine
liver and kidney by RT-PCR. Expression differences were
observed for variant O between Dalmatian and non-Dalmatian
in both liver and kidney (equivalent to isoform 2 in human) but not
for variant N (Figure 4A). Expression in the Dalmatian samples
was ,50% of non-Dalmatian levels in both tissues. SLC2A9
expression was further evaluated by RT-PCR using primers that
amplify both transcripts in 11 different tissues from an unaffected
Beagle. The highest levels of expression were observed in the
kidney and liver (Figure 4B).
Sequencing of the SLC2A9 gene was performed on canine liver
cDNA as well as genomic DNA so that intron/exon boundaries and
promoter regions could be evaluated. SLC2A9 coding exons 2–12, as
well as the exon-intron boundaries, were sequenced in a Dalmatian
and a Labrador Retriever. Six SNPs were discovered in the SLC2A9
sequence. Two are exonic; exon 5 G563T;Cys188Phe (nucleotide
and amino acid numbering are reported with reference to variant N)
and exon 11 G1303A;Val435Ile (nucleotide and amino acid
numbering are reported with reference to variant N), two are located
99 and 101 bp 59 to the start codon of variant O. SNPs were also
identified inintrons1 and 10. None ofthe intronic SNPsarewithin or
near conserved splice-site elements. The SLC2A9 exon 11 G1303A
Figure 3. Homozygosity mapping of the huu locus. The four genes located in this interval are presented at the top of the figure. A region of
CFA03 with distances in Mb above the line and marker locations below the line are shown. Genotypes across this region are shown in the boxed area.
The breed is listed in the first column using the following abbreviations: Dal, Dalmatian; BRT, Black Russian Terrier; BD, Bulldog; BX1, heterozygous
backcross dog; ND1 and ND2, mixed breed dogs; GA, genome assembly Boxer sequence. The different haplotypes are named in the second column,
and the number of times that they were observed is shown in the third column. SNP15, shown in red, is the candidate causal mutation in exon 5 of
SLC2A9. SNP9 and SNP10 are the promoter mutations in variant O. The common Dalmatian haplotype is shown in yellow, the non-Dalmatian
genotype is shown in blue, and heterozygous genotypes are shown in green. Microsatellite allele sizes are absent for the genome assembly Boxer
(GA) since DNA was not available for direct testing of the microsatellites.
doi:10.1371/journal.pgen.1000246.g003
Figure 4. Tissue and isoform expression of canine SLC2A9. (A)
Tissue expression by RT-PCR of canine SLC2A9 variant O, variant N, and
GAPDH. D is liver and kidney RNA isolated from a Dalmatian, and ND is
from a Newfoundland6Border Collie cross. (B) Tissue expression by RT-
PCR of canine SLC2A9 on top and the GAPDH control on the bottom.
Tissue samples from left to right are: 1 cerebellum, 2 cerebral cortex, 3
heart, 4 kidney, 5 liver, 6 skeletal muscle, 7 skin, 8 spinal cord, 9 spleen,
10 testis, 11 thymus.
doi:10.1371/journal.pgen.1000246.g004
SLC2A9 and Hyperuricosuria
PLoS Genetics | www.plosgenetics.org 4 November 2008 | Volume 4 | Issue 11 | e1000246SNP is polymorphic in the 24 unrelated Dalmatians tested, consistent
with its genomic location outside of the region homozygous in
Dalmatians (SNP17, Figure 3). The polymorphisms located 59 to the
start codon were tested in a panel of DNA samples from 15
unaffected dogs from various different breeds. Both SNPs are
polymorphic in unaffected non-Dalmatian dogs, displaying both the
Dalmatianhaplotype(A–C)andothercombinations.TheseSNPsare
always fixed in affected Dalmatian dogs (SNP9-10, Figure 3). Primary
sequence data from the exon 5 SNP is shown in Figure 5A.
The two non-synonymous SNPs found in SLC2A9 coding
sequence were tested using the PANTHER program (http://www.
pantherdb.org/tools/), which assigned the Cys188Phe substitution
a score of 24.047 (scores range between 0 to 210, 210 indicating
the most deleterious) with a probability that it is a deleterious
substitution of 0.74 [37]. The Val435Ile variation was not given a
prediction since the substitution is not conserved in other species
and unlikely to be deleterious. The SIFT program also scored the
Cys188Phe missense mutation as deleterious with a probability of
0.01, where any probability below 0.05 is considered deleterious
[38]. In order to evaluate the degree of protein conservation in the
region flanking the candidate SNP, SLC2A9 protein sequences
were compared between chicken, mouse, rat, human, Boxer and
Dalmatian (Figure 4B). This region of the protein has a high
degree of identity across mammals. The variant O promoter SNPs
(located 99 and 101 base pairs upstream of the initiator
methionine) were analyzed for transcription factor binding site
differences and the SNPs are predicted to disrupt binding sites for
DeltaE, AML-1a, S8 and Cre-BP in the Dalmatian version.
The SLC2A9 exon 5 C188F amino acid substitution was further
tested in 247 Dalmatians and 378 non-Dalmatian dogs from 58
different breeds. It was homozygous in all Dalmatians tested and
only the wildtype allele was present in the non-Dalmatian dogs.
Individual dogs from non-Dalmatian breeds are known to form
urate calculi and have been diagnosed with huu [39,40]. Two
Dogs from two of these breeds, Bulldogs and Black Russian
Terriers, that had formed urinary urate calculi were tested for the
SLC2A9 exon 5 G563T;Cys188Phe missense mutation (SNP 15 in
Figure 3) and the variant O promoter SNPS (SNP 9, 10 in
Figure 3) and found to be homozygous. These four dogs shared the
Dalmatian haplotype across the homozygous interval defined
during the positional cloning of the huu locus (Figure 3).
Discussion
The Dalmatian dog exhibits hyperuricosuria and relative
hyperuricemia due to a defect of urate transport in the liver and
kidney. Positional cloning of the huu locus using an interbreed
backcross, as well as homozygosity within the Dalmatian breed,
has identified SLC2A9 as the cause of the change in uric acid
handling by this dog breed. Unrelated breeds of dog with
hyperuricosuria or urate stone disease share the same haplotype
as Dalmatian dogs, providing compelling evidence that this is the
gene responsible. This result was somewhat unexpected because
SLC2A9 was classified as a member of the large glucose
transporter family and did not have an assigned function with
respect to urate transport until recently.
SLC2A9 is classified as a part of the large glucose transporter
family based on amino acid sequence identity of 44% and 38% to
Glut5 and Glut1, respectively [32]. SLC2A9 has been localized to
the cell surface in humans [34]. It contains 12 transmembrane
domains and, based on homology to other glucose transporters,
the central channel is essentially formed by helices 2, 4, 5, 7, 8, and
10 [41]. The Cys188Phe amino acid change occurs within a highly
conserved residue located within the fifth transmembrane domain
of the protein. Although a cysteine to phenylalanine amino acid
change is not expected to disrupt the localization of the alpha helix
to the transmembrane, this change could disrupt the proper
function of the protein by altering the pore. Precedent for single
amino acid changes altering substrate specificity has been shown
for a number of the SLC2A transporters [42].
Expression differences between Dalmatian and non-Dalmatian
samples were observed for one of the isoforms (O) of the gene
(Figure 4). SNPs in the promoter region of this variant were
identified and were fixed in the Dalmatian breed. These same
SNPs were also identified in non-Dalmatians without hyperuri-
cosuria. Therefore, these SNPs alone are not sufficient to confer
the phenotype but along with the missense mutation they may
contribute to the expression of the phenotype. It remains to be
determined if there are variant O transcript differences in the
general dog population and if the SNPs identified in this work are
responsible for the differences in the level of variant O expression.
In humans, the equivalent isoform to variant O is expressed on the
apical surface of the proximal tubules [34]. Reduction in the
amount of the protein combined with a deficiency in the protein
itself may contribute to the decreased conversion to allantoin by
the liver as well as the increased excretion of uric acid in these
dogs. SLC2A9 tissue expression in dogs is similar to that observed
in humans and mice. Expression in humans is highest in kidney,
Figure 5. Sequence and expression of canine SLC2A9. (A) The
electropherograms for the SLC2A9 sequence from a non-Dalmatian dog
(+/+), heterozygous backcross dog (+/huu), and a Dalmatian dog (huu/
huu) are shown. The nucleotide sequence is given, with the amino acid
sequence presented below. The box shows the location of the
mutation. (B) Protein sequence alignment of SLC2A9 around the exon
5 missense mutation from Dalmatians. The altered SLC2A9 amino acid is
indicated with a vertical arrow. The horizontal line indicates the fifth
transmembrane domain of the protein. The C. familiaris sequence is
shown for Boxer (B) and Dalmatian (D).
doi:10.1371/journal.pgen.1000246.g005
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within polarized canine kidney cells to the basolateral membrane
of the proximal tubules while isoform 2 is localized to the apical
side [34]. The tissue and cellular localization of SLC2A9 is
consistent with the Dalmatian huu phenotype and with SLC2A9
having a role in urate transport in both the liver and kidney.
Mutations in SLC2A9 will likely have important consequences
for a number of different disorders of uric acid homeostasis in
people. Significant alterations of SLC2A9 could cause primary
renal hypouricemia in people similar to SLC22A12 mutations
since genetic heterogeneity exists for this disorder [43–45].
Mutations in SLC2A9 could also cause cases of primary gout by
significantly altering the serum uric acid concentration. In
addition, more subtle changes could alter serum uric acid levels
by changing the amount of uric acid excreted in the urine. There
is evidence that polymorphisms in SLC22A12 are capable of
increasing serum uric acid levels in Japanese populations [46]. A
significant association of SLC2A9 to serum uric acid levels was
recently reported among Caucasian individuals [28] and among
Sardinian and Chianti cohorts [27]. Two other papers were
recently published on the importance of the SLC2A9 gene to urate
transport in humans. The first demonstrated that human SLC2A9
is a high capacity, low affinity uric acid transporter and that
genetic variants are associated with gout; however causative
mutations were not determined [30]. The second paper docu-
mented a strong association between SLC2A9 and uric acid levels
in cohorts of German and Austrian nationalities as well as a
correlation between RNA expression levels of this gene and serum
uric acid levels [29]. Thus, strong evidence exists that SLC2A9
functions as a urate transporter in humans, and likely in dogs.
In addition to the potential influence with respect to human uric
acid disorders, the present studies also impact our understanding
of the history of this defect in dogs. The story of hyperuricosuria in
dogs started in 1916 when Benedict first recognized the similarity
of uric acid defects in the Dalmatian dog and people [11].
However, the origin of this defect may have preceded the
development of the Dalmatian breed. The present studies show
that the same genetic mutation is present in Bulldogs and Black
Russian Terriers, breeds that are not known to be closely related to
the Dalmatian. It appears that affected individuals from these
breeds share the same haplotype as the Dalmatian, indicating that
the mutation is identical by descent between these breeds. The
mutation must be quite old since it would have to predate breed
formation; however, additional evaluation of the extended
haplotype in all three breeds is necessary to estimate an actual
age. Alternatively, although unlikely, the mutation could have
been introduced into these other breeds by crosses between breeds.
Although Dalmatians are fixed for hyperuricosuria, this is not true
of the other breeds. Therefore, genetic testing and selection in
those breeds can eliminate the disease. Within the Dalmatian
breed, the possibility exists for correction of this defect by the
introduction of unaffected Dalmatian6Pointer backcross dogs into
the purebred gene pool. These dogs are currently registered with
the United Kennel Club in the United States. The disease allele
probably became homozygous in modern Dalmatians through
selection for more distinctive spots. However, most low uric acid
excreting backcross dogs have acceptably sized spots (according to
the breed standard), allowing breeders the unique opportunity to
correct a fixed genetic defect while maintaining the breed
characteristic that may ultimately be responsible for its fixation.
Two independent lines of evidence from different species point
to the key role of SLC2A9 in urate transport; the Dalmatian uric
acid phenotype itself and genome wide association studies linking
SLC2A9 to uric acid levels in people along with direct uric acid
transport data. There are many questions to be answered about
the role of SLC2A9 in urate homeostasis and its other transport
functions. In dogs and other mammals with endogenously low
serum uric acid, SLC2A9 may normally play a different transport
role than in people where it appears to have an important function
in uric acid transport. Since degradation of uric acid to allantoin
does not occur in humans and great apes, SLC2A9 may play a
different role in transport in the liver as compared to those species
that excrete allantoin. The positional cloning of the hyperuricos-
uria locus in the Dalmatian dog has provided a compelling new
avenue of investigation toward a better understanding of urate
transport in mammals and successfully completes a story started in
1916 when Benedict first recognized the similarity of the uric acid
defect in the Dalmatian dog and people.
Materials and Methods
DNA samples from backcross dogs were acquired as previously
described [35]. The full pedigree of the dogs used in this analysis is
shown in Figure S1. Blood, buccal swab and DNA samples from
Dalmatians and non-Dalmatian dogs were obtained from patients
of the Veterinary Medical Teaching Hospital at UC Davis, the
UC Davis Veterinary Genetics Laboratory, Dr. Gary Johnson at
the University of Missouri, Columbia, and from private owners.
The use of animals in this research was approved by the University
of California, Davis animal care and use committee (protocol
#11962). Urine uric acid and creatinine was measured in 3–7
week old puppies as previously described [13].
LOD scores were calculated as previously described [35].
Primers for microsatellites spaced on average 100 Kb apart in the
3.3 Mb candidate region of CFA03 were identified using the May
2005 CanFam2.0 sequence assembly on the UCSC genome
browser and designed within sequence flanking each repeat using
the Primer3 program (Table S1) [47].
Eight SNPs, which are part of the Affymetrix canine SNP array,
were chosen because they are polymorphic in the general dog
population. Additional SNPs were mined from the canine genome
sequence or identified during sequencing of the candidate genes.
Primers for SNPs (Table S2) were designed as described above. SNP
and microsatellite sequences were PCR amplified and genotyped in
the backcross dogs and only informative markers for this family were
then genotyped in 24 unrelated purebred Dalmatians.
Human mRNA sequences were obtained from GenBank for
each of the candidate genes (MIST NM_052964.1, KIAA1729
NM_053042, WDR1 NM_005112.4, SLC2A9 AF210317). These
sequences were compared to the UCSC Genome Browser
annotation of the canine genome using the BLAT function to
obtain canine sequence for each gene. The Primer3 program was
used to design primers for the canine sequences (Table S3). PCR
reactions, genotyping and sequencing were done as previously
described [35]. Sequences were visualized using Chromas2
(Technelysium, Tewantin, QLD, Australia) and analyzed with
Vector NTI software (Informax, Frederick, MD, USA). TFsearch
Version 1.3 was used to analyze the Variant O promoter SNPs
affect on transcription factor binding sites.
59 and 39 RACE were performed for 3 of the 4 candidate genes.
RACE primers (Table S3) were designed as described above and
RACE products amplified with the SMART RACE cDNA
Amplification Kit (Clontech, Mountain View, CA, USA) and
cloned using the TOPO TA Cloning kit (pCR2.1-TOPO vector)
with One Shot TOP10 Chemically Competent E. coli (Invitrogen,
Carlsbad, CA, USA). Products were isolated with the Qiaprep
Spin Miniprep kit (Qiagen, Valencia, CA, USA) and sequenced as
described above. Genbank accession numbers for the transcripts
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are based on the May 2005 CanFAm2.0 genome assembly and are
viewed using the UCSC genome browser.
RNA was isolated from kidney and liver samples with the
Micro-FastTrack 2.0 mRNA isolation kit (Invitrogen, Carlsbad,
CA, USA). cDNA was synthesized with the SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA,
USA). Expression was evaluated for LOC479092, LOC611070
and both variants of LOC479093 from liver and kidney from
Dalmatians and unaffected Newfoundland6Border Collie crosses
using primers SLC59UTREx1VarNF and SLCR1 for variant N
and primers IntF-Ex1 and SLCR1 for variant O. The expression
of LOC479093 was also evaluated in an array of tissues from an
unaffected Beagle (cerebellum, cerebral cortex, heart, kidney, liver,
skeletal muscle, skin, spinal cord, spleen, testis and thymus) using
primers IntF5 and SLCdnaR. RNAs for these tissues were
acquired from Zyagen (San Diego, CA, USA) and cDNA
synthesized as described. GAPDH was amplified (F primer-
59AAGATTGTCAGCAATGCCTCC39, R primer -59CCAG-
GAAATGAGCTTGACAAA39) in these tissues to ensure that
equivalent amounts of cDNA were added.
SLC2A9 genotypes were determined by a restriction fragment
length polymorphism (RFLP) assay. PCR products were produced
as described previously using an unlabeled forward primer, 59-
TGCTTCTCTGAAATTTACCTCCA – 39 and a fluorescently
labeled reverse primer, 59-6FAM-CGAGAGGATGGTATACG-
GTGA -39 (Applied Biosystems, Foster City, CA). Products were
then digested with the enzyme HpyCH4V (New England Biolabs,
Ipswitch, MA) for 1 hour at 37uC. Digestions were analyzed on an
ABI 3100 Genetic Analyzer with GeneScan 400HD Rox size
standard. A 79 base pair unlabeled product is generated from the
440 bp product by a control cut site. The A allele produces a
labeled 361 base pair product and the G allele produces a labeled
106 base pair product.
Supporting Information
Table S1 Primers for microsatellite markers used to define the
Huu region.
Found at: doi:10.1371/journal.pgen.1000246.s001 (0.03 MB
XLS)
Table S2 Primers for SNPs used to define the Huu region.
Found at: doi:10.1371/journal.pgen.1000246.s002 (0.03 MB
XLS)
Table S3 Candidate gene primers.
Found at: doi:10.1371/journal.pgen.1000246.s003 (0.03 MB
XLS)
Figure S1 Numbers indicate that DNA was available; individual
3 is placed twice in the pedigree for clarity, individuals numbered
39 and higher were genotyped and phenotyped after Safra et al.
(2006). Standard genetic symbols are used for sex and affectation
status. The single male Pointer used in this pedigree is shown at
the top; all other dogs were purebred Dalmatians or backcross
progeny.
Found at: doi:10.1371/journal.pgen.1000246.s004 (12.17 MB
TIF)
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